Active Filter(s):
Details:
The presentation will highlight the continued safety and psychometric activity of the company's lead clinical molecule, SXC-2023, a drug designed to restore cognitive control over repetitive, maladaptive behaviors.
Lead Product(s): SXC-2023
Therapeutic Area: Psychiatry/Psychology Product Name: SXC-2023
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2020